OPKO Health Reports Q3 2026 Revenue Growth and Completes BioReference Asset Sale
OPKO Health (OPK) reported third-quarter 2026 consolidated revenue of $65.4 million, a 16% increase year-over-year driven by higher royalty income and product sales in its Global Products segment. A major strategic shift was highlighted by the $722 million cash sale of BioReference, marking the company's exit from clinical laboratory services to focus exclusively on biotechnology development. The company is leveraging significant liquidity, reporting $403.2 million in cash and restricted cash. While innovative biotech operating losses increased to $26.8 million due to higher R&D investments, management expects future upside through potential 4Kscore royalties of up to $150 million over the next decade. For the full year 2026, OPKO updated its revenue guidance to a range of $268 million to $278 million.
Topics: Asset Divestiture Biotechnology Revenue Growth Royalty Income
Read the full article at Motley Fool
Part of the story Heritage Global Reports Q3 2026 Revenue Growth Amid Strategic Shift to Asset-Light Model (7 articles)